Compare General Motors Company (GM) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Invesco Ltd. — how do they compare? General Motors Company trades at $77.55 (market cap $70.01B), while Invesco Ltd. trades at $30.45 (market cap $13.43B). The key difference: General Motors Company is far larger — about 5.2× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| GM | IVZ | |
|---|---|---|
Market Cap | $70.01B | $13.43B |
Sector | Consumer Cyclical | Financials |
52-Week High | $86.38 | $30.30 |
52-Week Low | $48.89 | $16.88 |
Enterprise Value | $173.34B | $23.68B |
Dividend Yield | 0.93% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $76.78, down 0.12% on the day, with a neutral technical signal and strong analyst support (63% buy ratings). Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $3.70 surpassing the $2.61 estimate. Revenue for 2025 was $185.02B, though net income margin narrowed to 1.38%. The company maintains solid cash flow from operations of $26.87B in 2025 and recently announced a $0.18 dividend for H1 2026.
GM presents a value opportunity with low P/S (0.4) and P/B (1.12) ratios, trading below the consensus price target of $102.00. Upside potential is supported by earnings beats and strategic investments in energy and autonomous driving, but risks include margin pressure, rising debt levels (46.79% debt-to-asset in 2024), and competitive auto market dynamics. Institutional sentiment remains bullish despite near-term headwinds.
Invesco (IVZ) trades at $30.50, up 6.16% in the past 24 hours, with a bullish technical signal from moving averages. The company reported mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $6.38 billion in 2025, though net income remained negative at -$281.70 million. Analyst consensus is divided with 12 buys and 16 holds, targeting $30.50 on average. Recent news highlights dividend declarations and AUM growth to $2.47 trillion as of June 2026.
The outlook for IVZ is cautiously optimistic, supported by strong cash flow from operations and upward earnings revisions. Key risks include persistent negative profit margins and competitive pressures in asset management. Upside potential hinges on execution improvements and market sentiment shifts, with the current price near the consensus target suggesting limited near-term movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
